Blog | Aug. 4, 2022 Key differences between HPV-positive and HPV-negative head and neck squamous cell carcinomas (HNSCC) Head and neck squamous cell carcinomas (HNSCC) develop from the mucosal epithelium in the oral…
Press Release | Jun. 2, 2022 Sysmex Inostics & QIAGEN Highlight Cancer Companion Diagnostics Alliance at ASCO 2022 Two poster presentations utilizing Sysmex Inostics technology to be featured Baltimore, MD, June 2, 2022…
Press Release | May. 24, 2022 Sysmex Inostics Expands Blood Test Offerings for Detection of Acute Myeloid Leukemia Joins Foundation for the National Institutes of Health Biomarkers Consortium Baltimore, MD, May 24, 2022…
Press Release | Feb. 22, 2022 Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference Presenting Poster of Clinical Trial Findings at 2022 Multidisciplinary Head and Neck Cancers Symposium Baltimore,…
Press Release | Jan. 26, 2022 University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients Baltimore, MD, January 26, 2022 – Sysmex Inostics, a global leader in the liquid biopsy…
Press Release | Oct. 20, 2021 New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal…
Press Release | Jul. 1, 2021 Sysmex Forms Strategic Alliance with QIAGEN to Provide Global Cancer Companion Diagnostics that Uses Ultra-sensitive Liquid Biopsy NGS Technology Sysmex Inostics is working to strengthen its global relationship with pharmaceutical companies in order to…
Blog | Jun. 8, 2021 New ASCO 2021 poster highlights HPV-SEQ test’s ultra-sensitive detection of HPV 16/18 in plasma Download our new poster, presented at the recent ASCO 2021 Annual Meeting: “Ultra-sensitive detection and…
Press Release | Jun. 2, 2021 Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated Plasma-Safe-SeqS cfHPV-DNA assay, is highly effective for measuring HPV DNA in the plasma of patients with OPSCC enrolled in the OPTIMA 2 treatment de-escalation trial. Baltimore, MD, 2021.06.02 – Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution…
Press Release | Apr. 10, 2021 Sysmex Inostics Presents Plasma-Safe-SeqS NGS Data at AACR for NSCLC Patients Sysmex Inostics Presents Data at AACR Demonstrating Plasma-Safe-SeqS NGS Liquid Biopsy Delivers Equivalent Performance to…
Publication | Dec. 8, 2020 Sysmex Inostics Presents Data Demonstrating Exquisite Sensitivity of Plasma-Safe-SeqS NGS Detection of MRD AML at ASH Annual Meeting Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity…
Press Release | Sep. 8, 2020 Sysmex Inostics’ Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management Baltimore, MD, 2020.09.08 – Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating…